MLANA and melanoma: In melanoma patients vaccinated with a mixture of Melan-A peptide combined with Montanide and CpG, the ability to elicit anti-Melan A CD8+ T cells expressing VLA-1, a surrogate marker of TRM, was correlated with better survival (40).